• Explore /
  • Poster
  • / INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.

INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer.

Abstract Poster

Authors

null

Martin T. King

Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, MA

Martin T. King , David R. Wise , Lawrence M. Scala , Neil M. Mariados , Amanda Whitbeck , Mark Pomerantz , Sharon Bober , Elai Davicioni , Glenn Bubley , Paul L. Nguyen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Prostate Cancer

Track

Prostate Cancer - Advanced,Prostate Cancer - Localized

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04025372

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr TPS384)

Abstract #

TPS384

Poster Bd #

Q4

Abstract Disclosures

Similar Posters

First Author: Guilhem Roubaud

First Author: Bertrand F. Tombal

First Author: Junlong Zhuang

First Author: Guillaume Grisay